GLP-1 therapy affects fertility in complex ways that matter before conception. Here is what women planning a pregnancy need to understand about stopping treatment, timing, and the metabolic benefits that can improve fertility.

For women of reproductive age on GLP-1 therapy who are thinking about pregnancy, either now or in the coming years, the intersection of this treatment with fertility and conception planning deserves a direct and clear conversation. There are dimensions of GLP-1 therapy that genuinely improve fertility, and there are reasons it needs to be stopped before conception that are equally important to understand.

Why GLP-1 Therapy Can Improve Fertility Before Conception

The metabolic improvements from GLP-1 therapy have direct effects on reproductive health that can improve fertility in women whose fertility was compromised by metabolic dysfunction.

Insulin resistance is one of the primary drivers of anovulation in women with PCOS, the most common cause of ovulatory infertility in reproductive-age women. As covered in the PCOS article, GLP-1 therapy's improvement in insulin sensitivity directly reduces the androgen overproduction that disrupts ovulation. Studies in women with PCOS consistently show that GLP-1 receptor agonists improve menstrual regularity and ovulatory frequency, which is the biological prerequisite for natural conception.

Body weight itself affects fertility through multiple pathways. Excess adipose tissue, particularly visceral fat, alters estrogen metabolism, produces androgens, and drives the systemic inflammation that impairs reproductive function. Women with obesity have higher rates of anovulation, longer time to conception, and higher rates of early pregnancy loss than women at healthy weight. The weight reduction from GLP-1 therapy addresses these pathways.

For women with PCOS or obesity-related infertility, the metabolic improvements from several months on GLP-1 therapy can meaningfully improve their fertility status before they try to conceive, even if the medication itself needs to be stopped before conception occurs.

Why GLP-1 Medications Need to Be Stopped Before Pregnancy

GLP-1 receptor agonists are not studied in pregnancy. The human safety data during pregnancy does not exist in the way it does for medications that have been used in pregnant women for decades. Animal studies with GLP-1 receptor agonists at high doses have shown adverse developmental effects in some species, which is the basis for the recommendation to discontinue the medication before conception.

This is not a theoretical precaution. The FDA and the clinical guidelines of major medical societies consistently recommend stopping GLP-1 medications before attempting conception. The standard recommendation is to discontinue treatment at least two months before trying to conceive, to allow the medication to clear the body completely before conception occurs.

Semaglutide has a half-life of approximately one week, but the pharmacological effects and tissue distribution take longer to fully resolve. The two-month washout recommendation provides a meaningful safety margin.

Planning the Transition

The transition off GLP-1 therapy in preparation for pregnancy is a clinical process that benefits from physician planning rather than simply stopping the medication when ready to try to conceive.

Weight regain after stopping GLP-1 therapy, as discussed in the weight regain article, can occur relatively quickly. For women who have used GLP-1 therapy to achieve metabolic improvements that improve fertility, maintaining those improvements after stopping requires a deliberate transition plan including nutritional habits and physical activity established during treatment.

Your EllieMD physician can work with you on this transition well before you intend to stop treatment, allowing time to establish the behavioral foundations that support maintaining metabolic health after the medication is discontinued. The two months between stopping the medication and beginning to try to conceive is the window in which these foundations are tested.

For women with PCOS whose fertility improvement was tied to reduced insulin resistance and more regular ovulation, maintaining dietary habits that support insulin sensitivity after stopping GLP-1 therapy is particularly important. The ovulatory improvements may persist for some time if insulin resistance remains controlled, or may begin to reverse if the metabolic gains are lost.

Contraception Considerations During Treatment

An important practical point for women on GLP-1 therapy who are not currently trying to conceive: the improved ovulatory function that GLP-1 therapy produces in women with PCOS means that women who were relying on irregular cycles as an informal indication of low fertility can no longer make that assumption once treatment begins.

Women who previously had infrequent or absent periods due to PCOS and assumed this meant low conception risk should be aware that GLP-1 therapy may restore more regular ovulation, and if pregnancy is not desired during treatment, appropriate contraception is important. Discuss this specifically with your EllieMD physician at the start of treatment.

What to Do When You Are Ready to Plan for Pregnancy

The conversation with your EllieMD physician about pregnancy planning should happen well before you are ready to conceive, ideally while still on active treatment. This timing allows your physician to assess your current metabolic status, design a transition plan that maximizes the maintenance of metabolic health after stopping, and ensure the washout period aligns with your conception timeline.

GLP-1 therapy can be a meaningful tool in preparing the metabolic environment for a healthier pregnancy, even though it cannot be used during pregnancy itself.

Individual results may vary. All prescriptions require approval by a licensed medical provider. Compounded medications are not FDA-approved. EllieMD facilitates access to independent healthcare providers and pharmacies and does not provide medical care or dispense medications.